Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas

References

• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev Drug Discov. 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. An overview of the alpha-, beta-and gamma-carbonic anhydrases from bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? J Enzyme Inhib Med Chem. 2015;30:325–332.
   PubMed Web of Science ®Google Scholar
• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112:4421–4468.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J. 2016;473:2023–2032.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases and metabolism. Metabolites. 2018;8:E25.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10:767–777.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets. 2015;19:1689–1704.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. New light on bacterial carbonic anhydrases phylogeny based on the analysis of signal peptide sequences. J Enzyme Inhib Med Chem. 2016;31:1254–1260.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. The eta-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin Ther Targets. 2015;19:551–563.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity. Future Med Chem. 2016;8:311–324.
   PubMed Web of Science ®Google Scholar
• Del Prete S, De Luca V, De Simone G, et al. Cloning, expression and purification of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum. J Enzyme Inhib Med Chem. 2016;31(sup4):54–59.
   PubMed Web of Science ®Google Scholar
• Xu Y, Feng L, Jeffrey PD, et al. Structure and metal exchange in the cadmium carbonic anhydrase of marine diatoms. Nature. 2008;452:56–61.
   PubMed Web of Science ®Google Scholar
• Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archaeal β-class (Cab) and γ-class (Cam) carbonic anhydrases. Curr Top Med Chem. 2007;7:901–908.
   PubMed Web of Science ®Google Scholar
• Schlicker C, Hall RA, Vullo D, et al. Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. J Mol Biol. 2009;385:1207–1220.
   PubMed Web of Science ®Google Scholar
• Del Prete S, De Luca V, Vullo D, et al. A new procedure for the cloning, expression and purification of the β-carbonic anhydrase from the pathogenic yeast Malassezia globosa, an anti-dandruff drug target. J Enzyme Inhib Med Chem. 2016;31:1156–1161.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites. 2017;7:E48.
   PubMed Web of Science ®Google Scholar
• Ward C, Langdon SP, Mullen P, et al. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev. 2013;39:171–179.
   PubMed Web of Science ®Google Scholar
• Kusuzaki K, Matsubara T, Murata H, et al. Natural extracellular nanovesicles and photodynamic molecules: is there a future for drug delivery? J Enzyme Inhib Med Chem. 2017;32:908–916.
   PubMed Web of Science ®Google Scholar
• Iessi E, Logozzi M, Mizzoni D, et al. Rethinking the combination of proton exchanger inhibitors in cancer therapy. Metabolites. 2018;8:E2.
   Web of Science ®Google Scholar
• Arechederra RL, Waheed A, Sly WS, et al. Effect of sulfonamides as carbonic anhydrase VA and VB inhibitors on mitochondrial metabolic energy conversion. Bioorg Med Chem. 2013;21:1544–1548.
   PubMed Web of Science ®Google Scholar
• Salameh TS, Shah GN, Price TO, et al. Blood-brain barrier disruption and neurovascular unit dysfunction in diabetic mice: protection with the mitochondrial carbonic anhydrase inhibitor topiramate. J Pharmacol Exp Ther. 2016;359:452–459.
   PubMed Web of Science ®Google Scholar
• Price TO, Sheibani N, Shah GN. Regulation of high glucose-induced apoptosis of brain pericytes by mitochondrial CA VA: A specific target for prevention of diabetic cerebrovascular pathology. Biochim Biophys Acta. 2017;1863:929–935.
   PubMed Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31:345–360.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat. 2000;10:575–600.
   Web of Science ®Google Scholar
• Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2012;27:759–772.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005-2013). Expert Opin. Ther. Pat. 2013;23:681–691.
   PubMed Web of Science ®Google Scholar
• Masini E, Carta F, Scozzafava A, et al. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin. Ther. Pat. 2013;23:705–716.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin. Ther. Pat. 2013;23:725–735.
   PubMed Web of Science ®Google Scholar
• Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008-2013). Expert Opin Ther Pat. 2013;23:737–749.
   PubMed Web of Science ®Google Scholar
• Carta F, Scozzafava A, Supuran CT. Sulfonamides (RSO2NH2): a patent review 2008-2012. Expert Opin Ther Pat. 2012;22:747–758.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Carta F, Supuran CT. Secondary and tertiary sulfonamides: a patent review (2008-2012). Expert Opin Ther Pat. 2013;23:203–213.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007-2011. Expert Opin. Ther. Pat. 2012;22:79–88.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat. Forthcoming 2018:1–9. DOI:10.1080/13543776.2018.1519023
   Google Scholar
• Hanff E, Zinke M, Böhmer A, et al. GC-MS determination of nitrous anhydrase activity of bovine and human carbonic anhydrase II and IV. Anal Biochem. 2018;550:132–136.
   PubMed Web of Science ®Google Scholar
• Chobanyan-Jürgens K, Schwarz A, Böhmer A, et al. Renal carbonic anhydrases are involved in the reabsorption of endogenous nitrite. Nitric Oxide. 2012;26:126–131.
   PubMed Web of Science ®Google Scholar
• Thiry A, Dognè JM, Masereel B, et al. Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem. 2007;7:855–864.
   PubMed Web of Science ®Google Scholar
• Aggarwal M, Kondeti B, McKenna R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23:717–724.
   PubMed Web of Science ®Google Scholar
• Hamidi S, Avoli M. Carbonic anhydrase inhibition by acetazolamide reduces in vitro epileptiform synchronization. Neuropharmacology. 2015;95:377–387.
   PubMed Web of Science ®Google Scholar
• Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett. 2003;13:841–845.
   PubMed Web of Science ®Google Scholar
• Angeli A, Supuran CT. Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist: a patent evaluation of CA2958110 and IN6616DEN2012. Expert Opin Ther Pat. Forthcoming 2018:1–5. DOI:10.1080/13543776.2018.1497160
   PubMedGoogle Scholar
• Supuran CT. Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother. 2015;15:851–856.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2016;12:423–431.
   PubMed Web of Science ®Google Scholar
• Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. Enzyme Inhib Med Chem. 2016;31:894–899.
   PubMed Web of Science ®Google Scholar
• Asides M, Ossipov MH, Kaila K, et al. Acetazolamide and midazolam act synergistically to inhibit neuropathic pain. Pain. 2010;148:302–308.
   PubMed Web of Science ®Google Scholar
• Carta F, Di Cesare Mannelli L, Pinard M, et al. A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects. Bioorg Med Chem. 2015;23:1828–1840.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother. 2016;16:961–968.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache. 2017;57:165–178.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase activators. Future Med Chem. 2018;10:561–573.
   PubMed Web of Science ®Google Scholar
• Briganti F, Mangani S, Orioli P, et al. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. Biochemistry. 1997;36:10384–10392.
   PubMed Web of Science ®Google Scholar
• Temperini C, Scozzafava A, Vullo D, et al. Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. Chemistry. 2006;12:7057–7066.
   PubMed Web of Science ®Google Scholar
• Temperini C, Scozzafava A, Vullo D, et al. Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design. J Med Chem. 2006;49:3019–3027.
   PubMed Web of Science ®Google Scholar
• Angeli A, Vaiano F, Mari F, et al. Psychoactive substances belonging to the amphetamine class potently activate brain carbonic anhydrase isoforms VA, VB, VII, and XII. J Enzyme Inhib Med Chem. 2017;32:1253–1259.
   PubMed Web of Science ®Google Scholar
• Canto de Souza L, Provensi G, Vullo D, et al. Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signal-regulated kinase in the cortex and the hippocampus. Neuropharmacology. 2017;118:148–156.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018). Expert Opin Ther Pat. 2018;1–12. DOI:10.1080/13543776.2018.1508453
   PubMedGoogle Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in amodel of breast cancer metastasis. J Med Chem. 2011;54:1896–1902.
   PubMed Web of Science ®Google Scholar
• Gieling RG, Babur M, Mamnani L, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem. 2012;55:5591–5600.
   PubMed Web of Science ®Google Scholar
• Krall N, Pretto F, Decurtins W, et al. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl. 2014;53:4231–4235.
   PubMed Web of Science ®Google Scholar
• Ferraroni M, Carta F, Scozzafava A, et al. Thioxocoumarins show an alternative carbonic anhydrase inhibition mechanism compared to coumarins. J Med Chem. 2016;59:462–473.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71:3364–3376.
   PubMed Web of Science ®Google Scholar
• Bozdag M, Carta F, Ceruso M, et al. Discovery of 4-hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 analogues for the treatment of hypoxic tumors overexpressing carbonic anhydrase IX. J Med Chem. 2018;61:6328–6338.
   PubMed Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013;32:5210–5219.
   PubMed Web of Science ®Google Scholar
• [cited 2018 Sep 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03450018.
   Google Scholar
• Winum JY. Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370). Expert Opin Ther Pat. Forthcoming 2018:1–3. DOI:10.1080/13543776.2018.1501472
   PubMedGoogle Scholar
• Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat. 2018;1–10. DOI:10.1080/13543776.2018.1497161
   Google Scholar
• Nishimori I, Minakuchi T, Morimoto K, et al. Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem. 2006;49:2117–2126.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Onishi S, Takeuchi H, et al. The alpha and beta classes carbonic anhydrases from helicobacter pylori as novel drug targets. Curr Pharm Des. 2008;14:622–630.
   PubMed Web of Science ®Google Scholar
• Joseph P, Ouahrani-Bettache S, Montero JL, et al. A new beta-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. Bioorg Med Chem. 2011;19:1172–1178.
   PubMed Web of Science ®Google Scholar
• Del Prete S, Isik S, Vullo D, et al. DNA cloning, characterization, and inhibition studies of an alpha-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. J Med Chem. 2012;55:10742–10748.
   PubMed Web of Science ®Google Scholar
• Güzel O, Maresca A, Scozzafava A, et al. Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. J Med Chem. 2009;52:4063–4067.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Minakuchi T, Vullo D, et al. Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. J Med Chem. 2009;52:3116–3120.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Minakuchi T, Maresca A, et al. The β-carbonic anhydrases from Mycobacterium tuberculosis as drug targets. Curr Pharm Des. 2010;16:3300–3309.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors? J Enzyme Inhib Med Chem. 2018;33:485–495.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Inhibition of bacterial carbonic anhydrases and zinc proteases: from orphan targets to innovative new antibiotic drugs. Curr Med Chem. 2012;19:831–844.
   PubMed Web of Science ®Google Scholar